Marisa Wexler, MS,  senior science writer—

An antibody biomarker may help to distinguish people with a disease that resembles multiple sclerosis (MS), but may actually be its own clinical disorder, according to a new study. The biomarker was present in about 1% of MS patients and in 6% of those with a related demyelinating condition…

A new imaging technique was able to detect inflammation in a mouse model of multiple sclerosis (MS) before disease symptoms appeared, and to monitor the animals’ responses to treatment, a study reports. “With this new non-invasive imaging approach, we can detect toxic inflammation that could help us better understand…

Estimates of the prevalence of sexual dysfunction with multiple sclerosis (MS), as well of its risk factors, differ depending on the specific cutoffs used to assess sexual health on a standardized test, a study highlights. Regardless of the cutoff given, however, findings suggest that patients with poorer cognition tend…

In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the disease develops have a strong impact on rates of disability worsening — but after about 2.5 years, more relapses don’t consistently result in a greater worsening of disability, according to…

Pro-inflammatory immune cells that can target the brain may be activated in a specific region of the intestine by certain gut bacteria before migrating to the brain, according to a new study done in mice. Researchers say these findings provide a proof of concept for how some immune cells may…

Octave Bioscience has raised $30 million in financing to help accelerate commercialization efforts for its precision care program for people with multiple sclerosis (MS). “We have made significant progress in deploying our solution for multiple sclerosis patients,” William Hagstrom, founder and CEO of Octave, said in a…

A new artificial intelligence (AI) algorithm could help identify people at risk of developing multiple sclerosis (MS). “Our model’s performance suggests that AI-based prediction models could identify the risk for multiple sclerosis years before neurological symptoms appear,” Raj Gopalan, MD, a scientist at Siemens Healthineers, Tarrytown, New York, said…

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that PB006, a biosimilar version of Tysabri (natalizumab), be approved to treat adults with highly active relapsing-remitting multiple sclerosis (RRMS). The recommendation comes about a year after the regulatory agency…

In multiple sclerosis (MS), inflammation leads to less energy production in nerve fibers by reducing the levels of enzymes in a key molecular pathway, called the TCA cycle, that cells use to generate energy, a new study shows. These findings imply that boosting activity of the TCA cycle might…

Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis (MS) that will test the company’s lead candidate, bryostatin-1 — a therapy designed to prevent cognitive deficits in MS patients. “We are moving forward with our clinical development plans for…

A first-of-its-kind study is aiming to determine whether older adults with multiple sclerosis (MS) can safely stop taking disease-modifying therapies, also known as disease-modifying agents (DMAs). The project is being led by scientists at the new P-HOPER Center, officially the Population Health Outcomes and Pharmacoepidemiology Education and Research…

With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…

Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased substantially, while injectable DMTs have become less popular, according to a study based on U.S. commercial health insurance data. “While two injectable therapies known as platform injectables, were once the…

A new formulation of Ocrevus (ocrelizumab), given as a 10-minute under-the-skin injection, was comparable to the approved intravenous version of the therapy in people with multiple sclerosis (MS), according to top-line results from a Phase 3 clinical trial. The medication’s developer, Roche, is planning to submit data from…

Inflammation in the membranes around the brain may trigger an inflammatory response that can spread into nearby brain tissue, a new study in a mouse model of multiple sclerosis (MS) shows. Researchers say these findings may help to advance scientists’ understanding of the mechanisms that underlie brain damage in…

The biopharmaceutical company Imcyse has signed on to a new project that aims to use artificial intelligence (AI) to develop tools that can be used to better track the progression of multiple sclerosis (MS). The project’s goal is to help guide treatment decisions for MS patients. Called Clinical…

Treatment with estriol, a hormone that’s produced during pregnancy, reduced disease severity and promoted myelin repair in the cortex — a key brain region affected in multiple sclerosis (MS) — in a mouse model of the disease. Those are the main findings of the study, “Neuroprotection in cerebral…

The PoNS device — officially the Portable Neuromodulation Stimulator, designed to help improve walking ability in people with multiple sclerosis (MS) — has been granted the accreditation needed for Medicare and Medicaid coverage in the U.S., according to Helius Medical Technologies, which makes the device. That designation, called…

Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting multiple sclerosis (RRMS), but disability progression outcomes are comparable between the therapies, an observational study of patients reported. “Study findings suggest that the effectiveness of rituximab on MS relapses was…

It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field has made substantial advances — including the approval of over two dozen medications — but there’s still a long way to go to improve care for progressive forms of…

The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially harmful nonself molecules, and helps to control the development of immune cells that are key for this process, a new study shows. Findings suggest that activating DDX39B with small molecules…

For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but certain forms of exercise may be better than others at improving specific measures of fitness, according to a review of multiple clinical trials. Results suggest that resistance training — pushing…

Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of multiple sclerosis (MS) — is driven in part by molecular mechanisms that are activated when microglia try to clear the corpses of dead myelin-making cells. That’s according to a new…

People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after switching to Kesimpta (ofatumumab), according to an analysis of data from the Phase 3 ARTIOS clinical trial. The patients previously were on Gilenya (fingolimod), or fumarate-based therapies such…

Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability due to multiple sclerosis (MS) in a mouse model of the neurodegenerative disorder, a new study shows. Use of the novel strategy even cured some of the animals. “We…

Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with distinct clinical features, new research shows. Given the variability of symptoms among people with MS, such groupings could help to improve individualized care for patients, according to Octave, a…

Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…

The European Commission has approved Briumvi (ublituximab) for the treatment of adults with relapsing forms of multiple sclerosis (MS) who have active disease, as defined by clinical or imaging features. The approval, which covers all member states in the European Union, as well as Iceland, Norway, and Liechtenstein,…

The average rate of relapses for multiple sclerosis (MS) in the modern era is lower than it has been in decades past, according to a new analysis from the U.K. Scientists speculate the availability of new, more effective disease-modifying therapies may help explain why relapses appear to…

Treatment with the cannabis oral spray nabiximols helped to relieve spasticity — increased muscle stiffness and spasms common in people with multiple sclerosis (MS) — among participants in two MS clinical trials, according to the results of a new analysis. “In this analysis, nabiximols was shown to significantly…